Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data At ASCO Annual Meeting

Cougar Biotechnology, Inc. (NASDAQ:CGRB) announced that results from ongoing Phase II clinical trials of Cougar’s investigational drug CB7630 (abiraterone acetate) were presented at the 2009 ASCO Annual Meeting that is currently taking place in Orlando, Florida. The data were released today in three poster presentations.

More: continued here

Filed under: Cancer on June 4th, 2009